EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease

The Clinical Practice Guidelines (CPG) propose recommendations for the diagnosis, treatment and follow-up of non-alcoholic fatty liver disease (NAFLD) patients and are the product of a joint effort by the European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). They update a position statement based on the 2009 EASL Special Conference [1] . The data have been retrieved by an extensive PubMed search up to April 2015. The final statements are graded according to the level of evidence and strength of recommendation, which are adjustable to local regulations and/or team capacities ( table 1 ) [2] . In particular, screening for NAFLD in the population at risk should be in the context of the available resources, considering the burden for the national healthcare systems and the currently limited effective treatments. The document is intended both for practical use and for advancing the research and knowledge of NAFLD in adults, with specific reference to paediatric NAFLD, whenever necessary. The final purpose is to improve patient care and awareness of the importance of NAFLD, and to assist stakeholders in the decision-making process by providing evidence-based data, which also takes into consideration the burden of clinical management for the healthcare system. Received: November 4, 2015 Accepted: November 4, 2015 Published online: April 8, 2016

[1]  J. Reinus,et al.  Extrahepatic Complications of Nonalcoholic Fatty Liver Disease. , 2016, Clinics in liver disease.

[2]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[3]  Marco Maggioni,et al.  Statin use and non-alcoholic steatohepatitis in at risk individuals. , 2015, Journal of hepatology.

[4]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[5]  F. Pattou,et al.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.

[6]  Asociacion Latinoamericana para el Estudio del Higado EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[7]  M. Carstensen,et al.  Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. , 2015, Cell metabolism.

[8]  E. Bugianesi,et al.  The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[9]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[10]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[11]  Z. Goodman,et al.  Current efforts and trends in the treatment of NASH. , 2015, Journal of hepatology.

[12]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  S. Friedman,et al.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop , 2015, Hepatology.

[14]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[15]  D. Brenner,et al.  Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial) , 2015, Hepatology.

[16]  N. Lundbom,et al.  Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes. , 2015, The Journal of clinical endocrinology and metabolism.

[17]  J. Borén,et al.  Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease , 2015, Hepatology.

[18]  S. Burks,et al.  Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. , 2015, Journal of hepatology.

[19]  G. Marchesini,et al.  NAFLD incidence and remission: only a matter of weight gain and weight loss? , 2015, Journal of hepatology.

[20]  B. Neuschwander‐Tetri,et al.  Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  F. Nascimbeni,et al.  Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease , 2014, Alimentary pharmacology & therapeutics.

[22]  H. Yki-Järvinen Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[23]  F. Pattou,et al.  Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease: A 5-Year Controlled Longitudinal Study , 2014, Annals of surgery.

[24]  J. Lavine,et al.  Review article: the management of paediatric nonalcoholic fatty liver disease , 2014, Alimentary pharmacology & therapeutics.

[25]  J. Jónasson,et al.  Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease , 2014, BMC Gastroenterology.

[26]  G. Frühbeck,et al.  Increased Cardiometabolic Risk Factors and Inflammation in Adipose Tissue in Obese Subjects Classified as Metabolically Healthy , 2014, Diabetes Care.

[27]  O. Cummings,et al.  No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. , 2014, Gastroenterology.

[28]  E. Gaudio,et al.  Nonalcoholic fatty liver disease and the heart in children and adolescents. , 2014, World journal of gastroenterology.

[29]  J. Dufour,et al.  Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. , 2014, Journal of hepatology.

[30]  H. Völzke,et al.  Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis , 2014, PLoS medicine.

[31]  K. Clément,et al.  TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease , 2014, Nature Communications.

[32]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. , 2014, Hepatology.

[33]  Deepak L. Bhatt,et al.  Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. , 2014, The New England journal of medicine.

[34]  L. N. Valenti,et al.  A 4-Polymorphism Risk Score Predicts Steatohepatitis in Children With Nonalcoholic Fatty Liver Disease , 2014, Journal of pediatric gastroenterology and nutrition.

[35]  G. Cho,et al.  Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population , 2014, Heart.

[36]  S. Saab,et al.  Impact of coffee on liver diseases: a systematic review , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[37]  L. N. Valenti,et al.  A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. , 2014, World journal of gastroenterology.

[38]  Xiaofei Wang,et al.  Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[39]  Lawrence A Leiter,et al.  Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials , 2014, European Journal of Clinical Nutrition.

[40]  J. George,et al.  The role of diet and nutritional intervention for the management of patients with NAFLD. , 2014, Clinics in liver disease.

[41]  M. Ngu,et al.  Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragments , 2014, Alimentary pharmacology & therapeutics.

[42]  G. Marchesini,et al.  The role of medications for the management of patients with NAFLD. , 2014, Clinics in liver disease.

[43]  L. Henry,et al.  Systematic review with meta‐analysis: non‐alcoholic steatohepatitis ‐ a case for personalised treatment based on pathogenic targets , 2014, Alimentary pharmacology & therapeutics.

[44]  H. Conjeevaram,et al.  Effect of lifetime alcohol consumption on the histological severity of non‐alcoholic fatty liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[45]  K. Cusi,et al.  Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. , 2014, Journal of hepatology.

[46]  M. Cole,et al.  Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. , 2014, Journal of hepatology.

[47]  M. Honda,et al.  The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial , 2014, Diabetologia.

[48]  M. Al-mallah,et al.  A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? , 2013, Atherosclerosis.

[49]  Federico Schena,et al.  Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial) , 2013, Hepatology.

[50]  P. Bedossa,et al.  A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. , 2013, Journal of hepatology.

[51]  S. Mudaliar,et al.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. , 2013, Gastroenterology.

[52]  J. Tomlinson,et al.  Non-alcoholic fatty liver disease in common endocrine disorders. , 2013, European journal of endocrinology.

[53]  B. Neuschwander‐Tetri,et al.  Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis , 2013, Alimentary pharmacology & therapeutics.

[54]  G. Ward,et al.  The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. , 2013, Journal of hepatology.

[55]  A. Burt,et al.  Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? , 2013, European journal of gastroenterology & hepatology.

[56]  G. Svegliati-Baroni,et al.  A 360-degree overview of paediatric NAFLD: recent insights. , 2013, Journal of hepatology.

[57]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[58]  H. Cortez‐Pinto,et al.  Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. , 2013, Journal of hepatology.

[59]  R. DeFronzo,et al.  Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease , 2013, Nutrients.

[60]  T. Therneau,et al.  Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States , 2013, Hepatology.

[61]  D. Torres,et al.  Physical activity: an essential component of lifestyle modification in NAFLD , 2012, Nature Reviews Gastroenterology &Hepatology.

[62]  V. Wong,et al.  Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease , 2012, The American Journal of Gastroenterology.

[63]  F. Negro,et al.  Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States , 2012, Medicine.

[64]  L. Gerber,et al.  Non‐alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population‐based study , 2012, Alimentary pharmacology & therapeutics.

[65]  M. Abraham,et al.  Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis , 2012, Hepatology.

[66]  Sung-il Cho,et al.  Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men , 2012, International Journal of Obesity.

[67]  A. Sanyal,et al.  Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). , 2012, Journal of hepatology.

[68]  A. Kahraman,et al.  Liver Transplantation in Nonalcoholic Steatohepatitis Is Associated with High Mortality and Post-Transplant Complications: A Single-Center Experience , 2012, Digestion.

[69]  N. Johnson,et al.  Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. , 2012, Journal of hepatology.

[70]  N. Chalasani,et al.  What Should We Recommend to Our Patients with NAFLD Regarding Alcohol Use? , 2012, The American Journal of Gastroenterology.

[71]  K. Watson,et al.  Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study , 2012, The Lancet.

[72]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[73]  Christopher D Byrne,et al.  Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? , 2012, European heart journal.

[74]  P. Vajro,et al.  Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents: Position Paper of the ESPGHAN Hepatology Committee , 2012, Journal of pediatric gastroenterology and nutrition.

[75]  Zhi‐Jie Zheng,et al.  Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. , 2012, The Journal of clinical endocrinology and metabolism.

[76]  D. Samuel,et al.  Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients. , 2012, Journal of hepatology.

[77]  Catriona A. Burdon,et al.  Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. , 2012, Journal of hepatology.

[78]  Kwok-Kin Wong,et al.  Metformin Prevents Liver Tumorigenesis by Inhibiting Pathways Driving Hepatic Lipogenesis , 2012, Cancer Prevention Research.

[79]  J. Hardies,et al.  Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) , 2012, Diabetes Care.

[80]  G. Frühbeck,et al.  Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity , 2012, International Journal of Obesity.

[81]  D. Kleiner,et al.  Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research , 2012, Seminars in Liver Disease.

[82]  C. Lawton,et al.  Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) , 2012 .

[83]  Christian Thoma,et al.  Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. , 2012, Journal of hepatology.

[84]  K. Clément,et al.  Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. , 2012, Journal of hepatology.

[85]  A. Feldstein,et al.  Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo‐controlled trial , 2011, Hepatology.

[86]  J. Heimbach,et al.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.

[87]  Shira Zelber-Sagi,et al.  Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. , 2011, World journal of gastroenterology.

[88]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[89]  Paolo Crosignani,et al.  Fatty liver index and mortality: The cremona study in the 15th year of follow‐up , 2011, Hepatology.

[90]  P. Rosenthal,et al.  Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. , 2011, JAMA.

[91]  B. Neuschwander‐Tetri,et al.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.

[92]  Christophe Tzourio,et al.  Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials , 2010, BMJ : British Medical Journal.

[93]  A. Alisi,et al.  I148M patatin‐like phospholipase domain‐containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease , 2010, Hepatology.

[94]  Enzo Bonora,et al.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.

[95]  N. Sattar,et al.  Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data , 2010, Hepatology.

[96]  Chris Day,et al.  A position statement on NAFLD/NASH based on the EASL 2009 special conference. , 2010, Journal of hepatology.

[97]  T. Berg,et al.  High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial , 2010, Hepatology.

[98]  D. Reboussin,et al.  Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes , 2010, Diabetes Care.

[99]  Rocio Lopez,et al.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.

[100]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[101]  E. Bugianesi,et al.  Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease , 2010, Hepatology.

[102]  V. de Lédinghen,et al.  Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations , 2010, Hepatology.

[103]  P. Giral,et al.  Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.

[104]  Julien Vergniol,et al.  Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease , 2010, Hepatology.

[105]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[106]  J. Newton,et al.  Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. , 2010, Journal of hepatology.

[107]  M. Raponi,et al.  Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. , 2009, World journal of gastroenterology.

[108]  J. Benson,et al.  The natural history of non-alcoholic fatty liver disease , 2006 .

[109]  W. Coyle,et al.  The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial , 2009, Therapeutic advances in gastroenterology.

[110]  B. Neuschwander‐Tetri,et al.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD—Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network , 2009, Hepatology.

[111]  K. Birkeland,et al.  Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial , 2009, Scandinavian journal of gastroenterology.

[112]  B. Neuschwander‐Tetri,et al.  Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial , 2009, Hepatology.

[113]  M. Simrén High- or Low-Carbohydrate Diets: Which Is Better for Weight Loss, Insulin Resistance, and Fatty Livers? , 2009 .

[114]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[115]  Philippe Giral,et al.  Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.

[116]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[117]  I. Guha,et al.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers , 2007, Hepatology.

[118]  A. Hakkarainen,et al.  Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. , 2008 .

[119]  Amalia Gastaldelli,et al.  Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.

[120]  L. N. Valenti,et al.  Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study , 2007, The American Journal of Gastroenterology.

[121]  A. Häkkinen,et al.  Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. , 2007, American journal of physiology. Endocrinology and metabolism.

[122]  Christian Gluud,et al.  Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. , 2007, JAMA.

[123]  J. Dufour,et al.  Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[124]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[125]  A. Alberti,et al.  Review article: chronic hepatitis C – natural history and cofactors , 2005, Alimentary pharmacology & therapeutics.

[126]  C. Nievergelt,et al.  Histopathology of pediatric nonalcoholic fatty liver disease , 2005, Hepatology.

[127]  Mark Fishbein,et al.  Hepatic MRI for Fat Quantitation: Its Relationship to Fat Morphology, Diagnosis, and Ultrasound , 2005, Journal of clinical gastroenterology.

[128]  G. Bedogni,et al.  Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study , 2005, Hepatology.

[129]  P. Giral,et al.  Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.

[130]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[131]  G. Marchesini,et al.  A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.

[132]  K. Petersen,et al.  Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.

[133]  S. Sanderson,et al.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.

[134]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[135]  A. Häkkinen,et al.  Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.

[136]  S. Caldwell,et al.  The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. , 2004, Journal of hepatology.

[137]  L. Burgart,et al.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.

[138]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[139]  C. Ryan,et al.  One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[140]  M. Roden,et al.  Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. , 2002, Diabetes.

[141]  Erick M Remer,et al.  The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[142]  G. Brandi,et al.  Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy , 2000, Annals of Internal Medicine.

[143]  P. Rosenthal,et al.  American Association for the Study of Liver Diseases , 1993, IDrugs : the investigational drugs journal.